On the other hand, in a retrospective study that examined the relationship between the level of NECTIN4 amplification in tumor tissue and prognosis in patients receiving EV monotherapy, nonamplified cases were found to have significantly shorter PFS and OS than amplified cases (p < 0.001). The gene discussed is NECTIN4; the disease is neoplasm.